Who
Heidi Hagen
Director
Company insider
Files Form 4 as: Director, Obsidian Therapeutics; Director, Vericel; Interim CEO, Alaunos Therapeutics.
In numbers
- Trades disclosed
- 68
- Buys
- 1
- Sells
- 2
- Bought
- $42K
- Sold
- $1.4M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 23 Aug 2013
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | OBX Obsidian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,653 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | OBX Obsidian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,653 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $41K15,000 at $2.76 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $486K15,000 at $32.41 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $41K15,000 at $2.76 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $486K15,000 at $32.41 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
News
No headline names them, or the companies they trade most, lately.